Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of “Buy” by Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been assigned a consensus recommendation of “Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a strong buy rating to the company.

A number of research analysts have recently issued reports on IKT shares. HC Wainwright raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a research report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research note on Tuesday, December 2nd. Finally, Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a report on Saturday.

Inhibikase Therapeutics Stock Up 21.2%

Shares of IKT opened at $2.00 on Friday. The company has a market capitalization of $150.36 million, a P/E ratio of -5.13 and a beta of 0.88. The firm’s 50 day moving average price is $1.56. Inhibikase Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.49.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.